JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials (Q36946580)

17 August 2017

1 reference

title

JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials (English)

1 reference

myeloproliferative disorders

17 August 2017

1 reference

Pardanani A

1

1 reference

17 August 2017

20 September 2007

1 reference

17 August 2017

1 reference

17 August 2017

22

1 reference

17 August 2017

1

1 reference

17 August 2017

23-30

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404948

17 August 2017

0 references

cites work

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

Erythroid colony formation by polycythemia vera bone marrow in vitro. Dependence on erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Polycythaemia vera: in vitro studies of circulating erythroid progenitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Polycythemia vera blood burst-forming units-erythroid are hypersensitive to interleukin-3.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Polycythaemia vera. III. Burst-forming units-erythroid (BFU-E) response to stem cell factor and c-kit receptor expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Molecular analysis of the erythropoietin receptor system in patients with polycythaemia vera

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

BCR-ABL and v-SRC tyrosine kinase oncoproteins support normal erythroid development in erythropoietin receptor-deficient progenitor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Signaling through the hematopoietic cytokine receptors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Jak2 is essential for signaling through a variety of cytokine receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Janus kinases affect thrombopoietin receptor cell surface localization and stability

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

A gain-of-function mutation of JAK2 in myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Characterization of murine JAK2V617F-positive myeloproliferative disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Activating alleles of JAK3 in acute megakaryoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Identification of an acquired JAK2 mutation in polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Lenalidomide therapy in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Allogeneic hematopoietic stem cell transplantation for myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

New strategies for immunosuppression: interfering with cytokines by targeting the Jak/Stat pathway.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Defective lymphoid development in mice lacking Jak3

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404948

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404948

1 reference

17 August 2017

1 reference

PubMed ID

17882282